@article{8b37b7db6e7a48e39ae50aceaf277c8d,
title = "Erdafitinib for locally advanced or metastatic urothelial carcinoma",
keywords = "efficacy, erdafitinib, FGFR alteration, safety, urothelial carcinoma",
author = "Siefker-Radtke, {Arlene O.} and Yohann Loriot",
note = "Funding Information: The BLC2001 clinical study was supported by Janssen Research & Development. Dr. Siefker-Radtke has received consulting fees from Janssen, Merck, NCCN, Bristol-Myers Squibb, AstraZeneca, Bavarian Nordic, Seattle Genetics, Nektar, Genentech, EMD Serono, Mirati Therapeutics, and Basilea; she has received research support from NIH, the Michael and Sherry Sutton Fund for Urothelial Cancer, Janssen, Takeda, Bristol-Myers Squibb, BioClin Therapeutics, Nektar, Merck Sharp and Dohme, and Basilea; and she helped develop a patent titled {"}Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.{"} Dr. Loriot has received consulting fees from Janssen, Astellas Pharma, Roche, AstraZeneca, MSD Oncology, Clovis Oncology, Seattle Genetics, and Bristol-Myers Squibb; he has received travel and accommodation expenses from Astellas Pharma, Janssen Oncology, Roche, AstraZeneca, MSD Oncology, Clovis Oncology, Seattle Genetics, and Bristol-Myers Squibb.",
year = "2022",
month = jun,
day = "1",
doi = "10.1093/ajhp/zxac030",
language = "English (US)",
volume = "79",
pages = "824--825",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "11",
}